Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor
In Reply: Drs Soumerai and Lipton
raise several questions concerning our study design. While we agree
that the quasi-experimental design used was less rigorous than the
randomized controlled trial as exemplified by efforts under way within
the Cochrane Collaboration, the main purpose of the article was to
demonstrate the effectiveness of a DUR program in a community setting.
State pharmacy laws require our pharmacies to conduct DURs for all
patients; the Merck-Medco Partners for Healthy Aging program represents
a specialized DUR for patients aged 65 years and older. Therefore, the
use of a control group as suggested by the authors would be against
public policy and in violation of state pharmacy laws.
Monane M, Matthias DM, Nagle BA, Kelly MA. Pharmaceutical Benefits Managers and Optimizing Prescribing—Reply. JAMA. 1999;281(13):1168. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-13-jbk0407
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: